Pandion Therapeutics Company
%20.jpg)
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.
Technology:
Regenerative Medicine
Headquarters:
Cambridge, Massachusetts, United States
Funding Status:
IPO
Founded Date:
2017-01-01
Last Funding Type:
Series B
Investors Number:
11
Estimated Revenue:
$1M to $10M
Employee Number:
11-50
Total Funding:
$138M
Industry:
Biotechnology, Health Care, Therapeutics, Wellness